At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
vorinostat +7 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B
In Brief
A clinical study evaluating vorinostat, anastrozole, and 6 other interventions for Male Breast Cancer and 2 related conditions. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionMar 2015
Study CompletionJan 2020
TodayJul 2026
First PostedNov 2, 2012
Enrollment StartNov 1, 2012
Primary CompletionMar 1, 2015
Study CompletionJan 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.7 years ago
Interventions
vorinostatdrug
Given PO
anastrozoledrug
Given PO
letrozoledrug
Given PO
exemestanedrug
Given PO
positron emission tomographyprocedure
Correlative studies
F-18 16 alpha-fluoroestradiolradiation
Correlative studies
fludeoxyglucose F 18radiation
Correlative studies
laboratory biomarker analysisother
Correlative studies